Confirmed Preliminary Control Closed Transaction verified Consumer Health

Lamisil acquired by Karo Healthcare

Karo Healthcare acquired Lamisil, a consumer healthcare / otc pharmaceuticals brand.

Preliminary: The transaction value is not yet independently verified.

Transaction summary

Target: Lamisil
Acquirer: Karo Healthcare
Seller: Haleon
Announced: 2023-08-01
Geography: -
Tags: Consumer Health
Type: Acquisition
Deal type: Control
Stake acquired: -
First added: 2026-06-19
Latest update: 2026-10-31

Value and multiples

100% enterprise value

GBP 235M

Unverified

100% enterprise value | GBP

Basis: Estimated

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

Approx. $300M USD using FX date 2023-08-01 at 1.2776 GBP/USD.

EV / revenue

4.1x

Period not stated

Basis: FundComb estimate

EV / EBITDA

EBITDA basis not stated

Basis: FundComb estimate

Amounts paid and other reported values

Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.

Consideration: GBP 235M

£235m.

Basis

The 4.1x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, revenue and period behind it are not stated. Karo Healthcare announced its acquisition of a majority stake in Lamisil from Haleon in 2023.

Source summary

No public source summary has been published for this transaction yet.

Continue your research

Explore more comps →

Same buyer / investor

E45 acquired by Karo Healthcare

2021-12-01 · Confirmed

View transaction → Same seller

ChapStick acquired by Suave Brands Company

2024-01-25 · Estimated

View transaction → Consumer Health

Vitabiotics acquired by Bain Capital

2026-07-24 · Confirmed